'Hypothetical' Suit Won't Shield Roche Patents From Review
The Patent Trial and Appeal Board on Thursday instituted inter partes reviews of two patents on Roche unit Chugai's arthritis and COVID-19 monoclonal antibody drug Actemra, ruling that "hypothetical future district...To view the full article, register now.
Already a subscriber? Click here to view full article